Drugs / UCENPRUBART
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06173895 | Jan → May 2024 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03750643 | Nov 2018 → Sep 2021 | atopic eczema | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT05911841 | Jun 2023 → Oct 2024 | atopic eczema | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 2 | NCT04159701 | Nov 2019 → Feb 2021 | chronic idiopathic urticaria | Eli Lilly and Company | Terminated | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UCENPRUBART | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314640 ↗ |
| Known as | LY3454738 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05911841 ↗ |
| Modality | Monoclonal antibody | — CHEMBL5314640 ↗ |
| Route | Intravenous | “Administered IV” NCT03750643 ↗ |